Valuation Newron Pharmaceuticals S.p.A. OTC Markets
Stocks
NWPHF
IT0004147952
Biotechnology & Medical Research
|
Delayed
OTC Markets
09:32:58 2026-03-31 EDT
|
5-day change | 1st Jan Change | ||
| 20.00 USD | +113.68% |
|
-.--% | +113.68% |
Company Valuation: Newron Pharmaceuticals S.p.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 27.93 | 27.99 | 94.91 | 185.1 | 511.9 | 180.5 | - | - |
| Change | - | 0.21% | 239.07% | 94.99% | 176.62% | -64.75% | - | - |
| Enterprise Value (EV) 1 | 27.93 | 60.23 | 114.7 | 225.7 | 521.2 | 194.7 | 198.6 | 180.5 |
| Change | - | 115.64% | 90.45% | 96.77% | 130.92% | -62.65% | 2.01% | -9.13% |
| P/E | -1.86x | -1.6x | -5.84x | 11.2x | -38.9x | -6.51x | 243x | 2.94x |
| PBR | - | -2x | -3.17x | 130x | -46x | - | - | - |
| PEG | - | -0.1x | 0.82x | -0x | 0x | -0.1x | -2x | 0x |
| Capitalization / Revenue | 4.85x | 4.59x | 10.5x | 3.6x | 26.8x | 21.3x | 4.53x | 1.5x |
| EV / Revenue | 4.85x | 9.88x | 12.7x | 4.39x | 27.3x | 22.9x | 4.98x | 1.5x |
| EV / EBITDA | -2.3x | -4.6x | -10x | 8.56x | -115x | -6.8x | 7.31x | 1.92x |
| EV / EBIT | -2.26x | -4.53x | -9.86x | 8.62x | -111x | -86.3x | 202x | 1.92x |
| EV / FCF | - | -5.42x | -11.3x | -12.8x | 16.1x | 2.63x | 3.26x | 1.74x |
| FCF Yield | - | -18.4% | -8.85% | -7.81% | 6.2% | 38% | 30.7% | 57.6% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.84 | -0.98 | -0.91 | 0.85 | -0.66 | -1.305 | 0.035 | 2.89 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 5.762 | 6.094 | 9.057 | 51.39 | 19.13 | 8.488 | 39.86 | 120 |
| EBITDA 1 | -12.15 | -13.1 | -11.43 | 26.36 | -4.525 | -28.63 | 27.16 | 94 |
| EBIT 1 | -12.36 | -13.3 | -11.63 | 26.17 | -4.697 | -2.255 | 0.9847 | 94 |
| Net income 1 | -14.9 | -17.49 | -16.22 | 15.84 | -13.24 | -29.99 | -1.956 | 58 |
| Net Debt 1 | - | 32.24 | 19.8 | 40.64 | 9.287 | 14.21 | 18.13 | - |
| Reference price 2 | 1.565 | 1.568 | 5.318 | 9.510 | 25.645 | 8.496 | 8.496 | 8.496 |
| Nbr of stocks (in thousands) | 17,845 | 17,845 | 17,845 | 19,459 | 19,961 | 21,239 | - | - |
| Announcement Date | 3/15/22 | 3/14/23 | 3/19/24 | 3/31/25 | 3/23/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.73x | 7.77x | 15.61x | 1.37% | 74.46B | |
| 31.25x | 9.01x | 28.06x | 0.04% | 60.14B | |
| 33.64x | 6.03x | 18.07x | 0.97% | 48.15B | |
| 34.63x | 3.34x | 14.4x | -.--% | 44.25B | |
| -21.16x | 229.18x | -22.81x | -.--% | 43.99B | |
| 47.94x | 5.54x | 30.43x | -.--% | 41.61B | |
| 26.89x | 7.76x | 19.96x | 0.42% | 29.97B | |
| 33.91x | 7.26x | 18.84x | -.--% | 29.31B | |
| -70.02x | 13.44x | -68.51x | -.--% | 24.93B | |
| Average | 15.42x | 32.15x | 6.01x | 0.31% | 44.09B | |
| Weighted average by Cap. | 19.58x | 31.88x | 10.24x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- NWRN Stock
- NWPHF Stock
- Valuation Newron Pharmaceuticals S.p.A.
Select your edition
All financial news and data tailored to specific country editions
